A COVID-19 vaccine developed by southwest China's Sichuan University has entered clinical trials in Japan. This is the first time a Chinese developed vaccine will undergo clinical trials there. The vaccine, which uses recombinant protein technology, obtained approval from Japan's Pharmaceuticals and Medical Devices Agency in mid-August. Phase one of the clinical trials began at the end of last month, with 240 healthy subjects enrolled and administered the vaccine to test its safety and efficacy. Researchers believe the risk of adverse reactions is very minor, as "recombinant protein vaccines" technology has already been used in other vaccines. 

WEI YU-QUAN Director, National Key Laboratory of Biotherapy, West China Hospital of Sichuan University "We use insect cells to make this type of vaccine. Prior to this, there had been no cases of industrialization using this technology in China, and there was no medicine produced using the technology, as it's difficult to develop. International companies like Sanofi have applied this technology to develop influenza vaccines. It can also be used to produce a cervical cancer vaccine. Based on our laboratory data, this vaccine has been effective in coping with the Delta variant. We're confident it will be successful."

This artical is originally is from CGTN. Link:https://news.cgtn.com/news/2021-09-15/VHJhbnNjcmlwdDU4NTg2/index.html